Managing Partner, VRS (Valuation & Research Specialists)

VRS (Valuation & Research Specialists)

Managing Partner

Valuation & Research Specialists (VRS) is a boutique financial advisor with more than 17 years of experience in Corporate Valuation and Finance, and a diversified client base including some of the largest Companies in Greece.

Since 2002, VRS has completed more than 200 engagements in the areas of business valuation and financial analysis for more than 100 clients in a wide range of industries.

VRS has been honored to work with small and large private and publicly traded companies in Europe and overseas.

Boutique Financial Advisor

Equity Bottom-Up

Aurinia Pharmaceuticals  / Equity Bottom-Up

<ul><li>Our estimations for 2023 annual revenue range around $157 million and for 2024 around $205 million.</li><li>The com- pany’s annual revenue reached $134.03 million in 2022 compared to $45.60 million in 2021, posting an increase by 194%.</li><li>Aurinia’s gross profit for 2022 was $128 million, increased by 188% compared to $45 million for the corresponding period of 2021.</li></ul>

Our estimations for 2023 annual revenue range around $157 million and for 2024 around $205 million.The com- pany’s annual revenue reached $134.03 million in 2022 compared to $45.60 million in 2021, posting an increase by 194%.Aurinia’s gross profit for 2022 was $128 million, increased by 188% compared to $45 million for the corresponding period of 2021.

Company Update - Aurinia Pharmaceuticals Inc.

Canada

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of immunosuppressive therapeutics.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00